Latest Ai In Drug Discovery News

Algorae Pharmaceuticals has advanced its AI-driven drug discovery platform into preclinical validation through a strategic collaboration with the Peter MacCallum Cancer Centre, while progressing its therapeutic pipeline and commercial leadership.

Opyl Limited unveils a bold strategic pivot to enhance its AI-driven drug discovery platform, leveraging a vast proprietary dataset and leadership upgrades to redefine clinical trial innovation.

Algorae Pharmaceuticals has secured a significant A$318,771 R&D tax incentive rebate from the Australian Taxation Office, providing a non-dilutive cash injection to advance its AI-driven drug discovery programs.

Algorae Pharmaceuticals has partnered with Peter MacCallum Cancer Centre to validate AI-predicted drug combinations across multiple cancer types, aiming to accelerate its oncology pipeline development.

Opyl Limited has successfully raised $1.5 million through an oversubscribed placement to accelerate the growth of its AI-driven clinical trial platform, Trialkey. The capital injection underscores strong investor confidence as the company prepares for a pivotal expansion phase.

Algorae Pharmaceuticals reports significant progress in its AI-driven drug discovery platform, unveiling 24 novel oncology targets and appointing a seasoned Chief Commercial Officer to bolster market readiness.